Meibomian Gland Dysfunction: The Oil-Gland Problem That Causes Most Dry Eye and Why It Must Be Addressed Before Eyelid Surgery

Most people researching blepharoplasty spend their time on scarring, recovery timelines, and before-and-after photos. Few ask about the small oil-secreting structures inside the eyelid margin - the ones sitting less than a millimeter from where a surgical incision lands. Meibomian gland dysfunction accounts for approximately 86% of all dry eye disease globally, and an estimated 72.86% of people who have it feel nothing at all. For anyone considering eyelid surgery, that silence is exactly the problem: the glands can be failing while the patient reports no symptoms, and surgery will make matters measurably worse. This guide explains what meibomian gland dysfunction is, how it is found, and why addressing it before - not after - blepharoplasty changes what patients experience on the other side of the procedure.

What Meibomian Glands Are and What They Do

The upper eyelid contains approximately 25 to 40 meibomian glands; the lower contains approximately 20 to 30. Each is a modified sebaceous gland embedded vertically in the tarsal plate, with a duct that opens at the posterior lid margin - the gray line visible at the inner edge of each eyelid when examined closely. Their job is to secrete meibum, a complex lipid mixture that forms the outermost layer of the tear film.

That lipid layer is less than 250 nm thick - thinner than a soap bubble - yet it performs two functions nothing else in the tear film can replicate. It seals the aqueous tears underneath, dramatically slowing evaporation between blinks, and it reduces surface tension at the air-tear interface so each blink spreads the film smoothly across the cornea instead of allowing it to fragment within seconds of opening the eye.

When meibum production falls or its composition becomes abnormal, the lipid layer thins. Aqueous tears evaporate faster. Tear film breakup time shortens, repeatedly exposing the corneal surface between blink cycles and triggering an inflammatory cascade that damages epithelial cells and feeds back into further gland dysfunction. What starts as a subtle secretion problem becomes a self-reinforcing cycle. Surgery lands directly in that cycle.

Two Types of MGD: How Each Develops and What It Looks Like

Not all MGD is the same disease. The two main categories differ in what goes wrong and in how they respond to treatment.

Obstructive MGD

The more common form begins with hyperkeratinization - overproduction of keratin by the cells lining the gland ducts. The duct openings narrow or cap with plugs of hardened secretion, trapping meibum inside. On examination, the lid margin shows capped orifices, irregular vascularization, and sometimes foam in the tear meniscus from abnormal meibum lipases interacting with bacteria. With sufficient obstruction, back-pressure gradually damages the secretory tissue inside the gland - eventually triggering dropout, the irreversible replacement of acinar cells with fibrous material. This is the form most amenable to in-office thermal-mechanical treatment because functional glands are still present; the goal is clearing the obstruction before dropout progresses further.

Hyposecretory MGD

Here the glands are atrophied rather than simply blocked. Output is low because there is less functional tissue - not because a plug prevents flow. The lid margin may look relatively unremarkable on casual inspection, but meibography reveals shortened, absent, or distorted structures. This form is more common in patients with long-standing untreated obstructive disease, in contact lens wearers with years of lens-induced gland shortening, and in older patients. Because the underlying problem is tissue loss, thermal-mechanical devices have considerably less to work with.

Who Gets MGD and Why

The global pooled prevalence of MGD is approximately 35.8%, and an estimated 70% of Americans over 60 have it. These numbers matter because the blepharoplasty-seeking population skews older and carries a disproportionate share of the specific risk factors that drive gland dysfunction.

• Age: Gland function declines progressively as acinar tissue shrinks, meibum viscosity increases, and duct compliance falls - independent of any other disease process.
• Rosacea: The inflammatory telangiectasias of rosacea run directly along the lid margin, delivering chronic heat and cytokines that damage meibomian ducts. Rosacea-associated MGD is both more severe and more responsive to IPL, which addresses both conditions at the same time.
• Contact lens wear: Long-term lens wear is independently associated with meibomian gland shortening and dropout over time. Many blepharoplasty candidates have worn lenses for decades and may have subclinical gland loss they have never been screened for.
• Screen time: Average blink rate drops from roughly 15 blinks per minute in normal conversation to 5-7 blinks per minute during concentrated screen use. Each full blink physically expresses meibum from the glands - spend hours a day with partial blinks and duct contents thicken, stagnate, and plug.
• Hormonal changes: Estrogen and androgen receptors are expressed in meibomian gland tissue. Postmenopausal shifts - particularly declining androgens - reduce meibum production and alter its composition.
• Sun exposure combined with air conditioning: High cumulative UV exposure drives lid margin inflammation and rosacea flares; aggressive indoor air conditioning keeps ambient humidity chronically low, stressing the lipid tear layer every day. For patients in South Florida, this pairing is not an occasional circumstance - it is the baseline environment. Generic national health pages on MGD mention neither.

How MGD Is Diagnosed

A thorough pre-surgical ocular surface evaluation involves several steps, each capturing a different aspect of gland status and tear film stability. Because most MGD is asymptomatic, no single test is sufficient on its own.

1. Symptom questionnaire (OSDI or DEQ-5): Standardized instruments put a numerical score on dryness, irritation, and visual symptoms. A low score does not rule out MGD - it establishes a baseline.
2. Slit-lamp lid margin examination: The examiner looks for capped or plugged duct orifices, lid margin thickening and irregularity, telangiectasias running to the lid edge, and foam in the tear meniscus. These are the clinical signs of obstructive disease.
3. Meibum expressibility grading: Gentle pressure applied through the outer lid expresses gland contents. Normal glands yield clear, oily meibum readily. Obstructed glands produce cloudy, toothpaste-thick secretion or nothing at all. Grading quality and ease of expression gives a direct, real-time reading of current gland function.
4. Tear film breakup time (TFBUT): Fluorescein dye is instilled and the patient observed under cobalt-blue light. The elapsed time from the last blink to the first corneal dry spot reflects lipid-layer stability - a short breakup time points to meibomian insufficiency rather than aqueous deficiency.
5. Schirmer testing: Paper strips inside the lower lid measure aqueous tear production over five minutes, distinguishing evaporative dry eye (lipid-layer failure) from aqueous-deficient dry eye (lacrimal gland failure). Many patients have both.
6. Non-contact infrared meibography: This is the step that changes clinical decisions. An infrared camera images the gland structures through the everted lid, mapping their length, number, and shape. Healthy glands appear as parallel, full-length white structures. Dropout shows as dark gaps - absent or foreshortened tissue. In one screening study of refractive surgery candidates, 49.9% had high-grade MGD on meibography, the majority without any symptoms.

Why MGD Is a Preoperative Issue, Not an Afterthought

The connection between blepharoplasty and gland damage is now supported by direct clinical evidence. A recently published study of full-incision double-eyelid blepharoplasty found statistically significant worsening of OSDI dry eye scores, meibum quality, meibomian gland expressibility, and incomplete blinking rate at both one week and one month after surgery. The procedure itself - not simply the postoperative environment - impairs gland function in a documented, measurable way.

What makes this clinically serious is the irreversibility of gland dropout. Once acinar tissue is replaced by fibrous material, it cannot regenerate. Treatment preserves functional glands; it does not restore what has already been lost. A patient who enters surgery with partially compromised glands and loses additional function during the operative and healing period cannot recover back to their presurgical baseline. They descend further along a one-way gradient.

The case for preoperative treatment is not theoretical. A prospective randomized clinical trial demonstrated that treating MGD before cataract surgery - another anterior-segment procedure that disrupts the ocular surface - significantly reduced the aggravation of gland dysfunction and dry eye induced by surgery compared with no preoperative treatment. The same physiologic logic applies to blepharoplasty. Surgeons who evaluate the skin, orbital fat, and muscle but skip the ocular surface evaluation are bypassing the factor that most directly determines how well the eye tolerates what comes next. The dry eye complications that blepharoplasty patients report after surgery are, in a large share of cases, the downstream result of pre-existing MGD that was never identified.

Feeling fine before surgery does not mean the glands are fine. And after surgery is too late to find out.

Home Management: What It Helps and Where It Falls Short

Home care is appropriate for mild MGD and as ongoing maintenance after in-office treatment. For moderate or severe disease - and especially for a patient planning an elective eyelid procedure - it is insufficient on its own.

Warm compresses

The goal is to raise lid margin temperature enough to liquefy inspissated meibum so normal blinking can express it. A wet washcloth cools within 90 seconds. Dedicated heat masks that maintain a consistent temperature for ten to fifteen minutes are more effective. Even so, home compresses deliver less precise and less sustained heat than clinical devices, and they provide no mechanical expression of gland contents.

Lid hygiene

Cleaning the lid margin removes keratin debris and bacterial biofilm that contribute to duct obstruction. Commercial hypochlorous acid sprays and tea-tree-oil-based cleansers are more targeted than diluted baby shampoo because they address the specific microorganisms - including Demodex mites and their associated bacteria - that drive chronic lid margin inflammation. Patients with concurrent Demodex blepharitis, covered in depth separately on this site, need a cleanser selected for that specific pathogen, not general soap.

Omega-3 supplementation

Oral omega-3 fatty acids (EPA and DHA) influence meibum composition by shifting the lipid profile toward more fluid, less inflammatory secretion. Evidence supports a modest benefit for symptom scores and tear breakup time with consistent use over several months - an adjunct, not a primary treatment, and not fast enough to address the pre-surgical timeline in most cases.

What home management cannot accomplish: clearing established duct obstruction in moderate-to-severe disease, arresting gland dropout, or providing the gland-protective effect before surgery that in-office treatment can. When meibography shows significant gland loss in a blepharoplasty candidate, clinical intervention is warranted before the procedure is scheduled.

In-Office Thermal Pulsation and Heat-Expression Devices

Three FDA-cleared devices apply controlled heat to the eyelids and add mechanical expression or pulsation to clear obstructed ducts. They differ primarily in where heat contacts the lid.

LipiFlow has the largest published evidence base. It heats the inner eyelid surface to precisely 42.5 degrees Celsius - the temperature at which meibum liquefies without damaging lid tissue - while automated pulsed pressure from the outer side simultaneously expresses the softened contents during a session of approximately 12 minutes. A single treatment improved meibum production and symptoms in approximately 80% of patients in clinical trials, with published clinical trial data documenting improvements across follow-up periods ranging from one to twelve months.

TearCare received FDA clearance specifically for MGD-related evaporative dry eye, with language covering improvement of meibomian gland function itself - not only symptom relief. This distinction matters: TearCare is the first device cleared with an indication that speaks to the glands rather than only the patient's subjective experience of dryness. Patients keep their eyes open and blink normally during heating, which may enhance expression of meibum through natural blink mechanics before the clinician performs a manual expression pass. iLux uses a handheld applicator the clinician positions gland by gland, allowing targeted treatment of segments identified on meibography as most affected.

IPL for MGD: The Dual Benefit That Most Aesthetic Guides Miss

Intense pulsed light applied to the periocular region does something beyond improving skin tone. The light energy closes the abnormal telangiectasias on the lid margin that are the primary inflammatory driver in rosacea-associated MGD - delivering heat that liquefies inspissated meibum while simultaneously reducing the cytokine environment that accelerates gland dropout. It also reduces the Demodex population on the periocular skin and lids, removing one more source of chronic duct inflammation.

Randomized controlled trial data show that IPL plus meibomian gland expression improved dry eye symptoms in 89% of patients and meibomian gland function in 77%. Symptom improvements begin as early as three weeks after the first session and persist approximately ten months after the final treatment - a durability profile that is clinically useful for patients working to stabilize their ocular surface before an elective procedure.

For patients in South Florida, the rosacea-MGD connection changes the calculus. Rosacea is common in fair-skinned individuals with high lifetime UV exposure. Rosacea-associated telangiectasias are both a cosmetic concern and a direct cause of lid margin inflammation. IPL addresses both simultaneously: a patient who comes to a consultation asking about facial redness may be an ideal candidate for IPL-based MGD treatment before blepharoplasty - a connection that rarely gets made in oculoplastic workflows that treat the face and the ocular surface as separate concerns. Generic photofacial pages on this site's topic cover the cosmetic benefit; they do not explain that the therapeutic MGD effect is produced by the same mechanism.

The standard IPL protocol for MGD involves three to four sessions spaced four to six weeks apart, with meibomian gland expression performed at each visit. The spacing is intentional: each treatment reduces inflammation and softens meibum sequentially, with gland function continuing to improve between sessions. Some patients with severe disease or concurrent rosacea require maintenance sessions - typically once or twice a year - to sustain the benefit over time.

Long-Term Management and What Patients Should Expect

MGD is progressive and chronic. The glands lost to dropout before diagnosis are gone. Treatment slows further loss and preserves functional glands. Patients who understand this distinction maintain more realistic expectations and are more likely to follow through with the ongoing care the condition requires rather than treating a single LipiFlow session as a cure.

After blepharoplasty in a patient with pre-existing MGD - even one that was treated preoperatively - the operative insult itself creates a window of additional stress on the ocular surface. Disrupted orbicularis mechanics, temporary lagophthalmos during early healing, and reduced blink completeness all impose demands on glands that are already operating below their original capacity. Post-surgical ocular surface reassessment should be built into the follow-up plan from the start, not left for the patient to request when symptoms appear.

A sustainable maintenance plan after MGD treatment typically involves:

• Daily lid hygiene with an appropriate cleanser as a permanent habit, not a temporary treatment course
• Scheduled reassessment of meibum expressibility and tear breakup time - annually at minimum, more frequently in patients with significant dropout at baseline
• Repeat in-office device treatment or IPL sessions when follow-up shows declining gland function, rather than waiting for symptoms to emerge
• Low-dose oral doxycycline as a clinician-guided adjunct for patients with rosacea-associated disease during flares - at the guidance of a treating physician who can assess current dosing recommendations and duration appropriate for the individual
• Serial meibography to compare gland maps over time and determine whether dropout is stable or progressing

When a patient with known MGD considers any additional eyelid procedure in the future, the same pre-surgical evaluation applies again. MGD status at that point reflects what gland tissue remains after prior procedures, years of aging, and whatever maintenance has or has not been maintained. It is not a one-time checkbox. It is an ongoing measurement that must be re-established before any intervention that touches the lid margin.

Frequently Asked Questions

Can someone have meibomian gland dysfunction without any dry eye symptoms?

Yes - and this is the most clinically important fact about MGD for surgical candidates. An estimated 72.86% of people with the condition have no symptoms at the time they are imaged. Glands can show significant shortening and dropout on infrared meibography while the patient reports no dryness, grittiness, or discomfort whatsoever. This is precisely why meibography - not a symptom questionnaire - is the decisive screening tool before an elective eyelid procedure.

How is MGD different from other types of dry eye?

Aqueous-deficient dry eye is a failure of the lacrimal gland to produce enough water-based tears. MGD is a failure of the meibomian glands to produce the lipid layer that sits on top of those tears and prevents them from evaporating. Both produce a dry, irritated eye, but the mechanism, tear-film profile, and treatment approach are different. Many patients have both simultaneously, which is why a full multi-step evaluation - not a single test - is needed to characterize what is actually driving symptoms and which intervention to prioritize.

Does blepharoplasty cause MGD or worsen existing disease?

A recently published study that measured meibomian gland function before and after full-incision blepharoplasty found statistically significant worsening of function at one week and one month post-surgery - documenting that the procedure itself impairs gland function. Whether surgery can initiate de-novo MGD in entirely healthy glands or primarily accelerates existing subclinical disease is not fully resolved by current evidence. The practical implication is the same either way: assess and treat the glands before the procedure, not after complications appear and dropout has already advanced.

Why does IPL for a photofacial also help meibomian glands?

IPL closes the abnormal lid-margin telangiectasias that deliver chronic inflammatory signals directly to meibomian ducts - this is the dominant mechanism in rosacea-associated MGD, not simply a side effect of treating nearby skin. The light energy also generates warmth that liquefies obstructed meibum and reduces the Demodex populations that contribute to chronic duct inflammation. The cosmetic and therapeutic effects are produced by the same treatment applied to the same tissue, which is why IPL is a logical choice for patients who have both rosacea-related skin concerns and pre-surgical MGD to address before blepharoplasty.

How should patients find a provider experienced in pre-surgical MGD evaluation?

The evaluation requires access to meibography equipment and experience grading meibum expressibility and tear film parameters - tools and skills more common in ophthalmology practices that specialize in ocular surface disease than in general optometry or cosmetic surgery offices. The American Academy of Ophthalmology's physician-finder tool at aao.org and the Tear Film and Ocular Surface Society's resources at tearfilm.org can help identify practitioners with specific dry eye and anterior-segment expertise. When consulting with a blepharoplasty surgeon, it is worth asking directly whether meibography is included in the preoperative workup or whether a separate referral to an ocular surface specialist is recommended before scheduling.